Cure Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)Cam Gallagher(Executive Officer, Director)inJohn Maroney(Executive Officer, Director)
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)in
Board seatAnnie Mitsak· per SEC Form D
Co-investorsMission Bay CapitalMission Biocapital
BiotechBoston, US
Ronald D. Seidel, III(Executive Officer, Director)
BoardCameron Gallagher(Director)Rodolfo Chaparro(Director)Andrew King(Executive Officer)in
Board seatLou Tartaglia· per SEC Form D
Unlocking post-translational protein modification using chemical biology and computational approaches to develop drugs for previously undruggable oncology targets.
BiotechCambridge, US
Xu Wu(Director)
BoardSeth Lieblich(Director)inMichael Aberman(Director)Drew King(Executive Officer)Milenko Cicmil(Executive Officer, Director)
Board seatDavid Fallace· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.